Venetoclax
- Generic Name
- Venetoclax
- Brand Names
- Venclexta, Venclyxto
- Drug Type
- Small Molecule
- Chemical Formula
- C45H50ClN7O7S
- CAS Number
- 1257044-40-8
- Unique Ingredient Identifier
- N54AIC43PW
- Background
Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leu...
- Indication
本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Associated Therapies
- -
Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2014-09-26
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 116
- Registration Number
- NCT02250937
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 445
- Registration Number
- NCT02242942
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇮🇹Az. Osp. S. Maria; Dept. Di Oncologia Medica, Terni, Umbria, Italy
🇦🇹Wilhelminenspital; I. Medizinische Abt., Wien, Austria
Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 212
- Registration Number
- NCT02203773
- Locations
- 🇺🇸
Johns Hopkins University /ID# 129699, Baltimore, Maryland, United States
🇺🇸Northwestern University Feinberg School of Medicine /ID# 128741, Chicago, Illinois, United States
🇺🇸Dana-Farber Cancer Institute /ID# 127857, Boston, Massachusetts, United States
A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)
- Conditions
- Interventions
- First Posted Date
- 2014-07-11
- Last Posted Date
- 2019-06-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 163
- Registration Number
- NCT02187861
- Locations
- 🇦🇺
Royal Prince Alfred Hospital; Medical Oncology, Camperdown, New South Wales, Australia
🇧🇪Cliniques Universitaires St-Luc, Bruxelles, Belgium
🇧🇪ZNA Stuivenberg, Antwerpen, Belgium
A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy
- First Posted Date
- 2014-05-19
- Last Posted Date
- 2022-12-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 127
- Registration Number
- NCT02141282
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center /ID# 134509, Boston, Massachusetts, United States
🇺🇸University of Utah /ID# 130813, Salt Lake City, Utah, United States
🇺🇸Moores Cancer Center at UC San Diego /ID# 128535, La Jolla, California, United States
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients with Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
- Conditions
- Acute Biphenotypic LeukemiaAcute Myeloid LeukemiaBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveBlasts 10 Percent or More of Bone Marrow Nucleated CellsBlasts 10 Percent or More of Peripheral Blood White CellsDe Novo Myelodysplastic SyndromeMyelodysplastic SyndromePreviously Treated Myelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Interventions
- First Posted Date
- 2014-04-16
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 508
- Registration Number
- NCT02115295
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL
- Conditions
- Interventions
- First Posted Date
- 2014-02-05
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 267
- Registration Number
- NCT02055820
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇦🇺Royal Melbourne Hospital, Parkville, Victoria, Australia
🇦🇹Medizinische Universität Wien, Wien, Austria
A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2013-12-09
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 389
- Registration Number
- NCT02005471
- Locations
- 🇧🇪
Cliniques Universitaires Saint-Luc; Hematology, Bruxelles, Belgium
🇺🇸Huntsman Cancer Institute; University of Utah, Salt Lake City, Utah, United States
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2013-11-26
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 32
- Registration Number
- NCT01994837
A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 12
- Registration Number
- NCT01969669
- Locations
- 🇺🇸
Site Reference ID/Investigator# 97498, Tucson, Arizona, United States
🇺🇸Site Reference ID/Investigator# 92593, Lebanon, New Hampshire, United States
🇺🇸Site Reference ID/Investigator# 101415, Hackensack, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.